Evaluating the Efficacy of Atomoxetine in Reducing Primary Nocturnal Enuresis in Children With ADHD: A Randomized, Placebo-Controlled Study

Launched by TANTA UNIVERSITY · Feb 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a medication called atomoxetine in helping children with Attention Deficit Hyperactivity Disorder (ADHD) who also experience bedwetting, known as primary nocturnal enuresis. The main goal is to see if atomoxetine can reduce the number of bedwetting episodes in these children. Researchers are also interested in finding out if improvements in attention problems are linked to fewer bedwetting incidents.

To participate, children must be between 6 and 12 years old and diagnosed with ADHD. They should also be experiencing bedwetting. However, children with other medical issues that could cause bedwetting, or those who are already taking treatments for it, won't be eligible. The trial is not yet recruiting participants, but if enrolled, families can expect to contribute to important research that may help improve the lives of children facing these challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children aged 6-12 years diagnosed with ADHD per Conners-48 scale. Children experiencing primary nocturnal enuresis.
• Exclusion Criteria:
• • Secondary causes of enuresis (e.g., urinary tract infections, diabetes). Use of other enuresis treatments. Known contraindications to atomoxetine.